[{"AccountsPayableCurrent_0_Q2_USD":3406000.0,"PaymentsToAcquireMarketableSecurities_2_Q2_USD":42639000.0,"PaidInKindInterest_2_Q2_USD":172000.0,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2_Q2_USD":-3000.0,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1_Q2_USD":-16000.0,"OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2_Q2_USD":-3000.0,"OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1_Q2_USD":-16000.0,"OtherAssetsNoncurrent_0_Q2_USD":2445000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":1000.0,"OperatingLeaseWeightedAverageDiscountRatePercent_0_Q2_pure":0.0535,"OperatingLeaseRightOfUseAsset_0_Q2_USD":40674000.0,"OperatingLeasePayments_2_Q2_USD":4799000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":54803000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":6840000.0,"OperatingLeaseLiability_0_Q2_USD":61643000.0,"OperatingLeaseCost_2_Q2_USD":3773000.0,"OperatingLeaseCost_1_Q2_USD":1886000.0,"OperatingIncomeLoss_2_Q2_USD":-46391000.0,"LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_0_Q2_USD":0.0,"LongTermDebtNoncurrent_0_Q2_USD":20000000.0,"MarketableSecurities_0_Q2_USD":16107000.0,"MarketableSecuritiesUnrealizedGainLoss_1_Q2_USD":-16000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":173000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":73828000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":3003000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-41630000.0,"NetIncomeLoss_2_Q2_USD":-46097000.0,"NonoperatingIncomeExpense_1_Q2_USD":150000.0,"NonoperatingIncomeExpense_2_Q2_USD":294000.0,"OperatingExpenses_1_Q2_USD":23540000.0,"OperatingExpenses_2_Q2_USD":46956000.0,"OperatingIncomeLoss_1_Q2_USD":-23261000.0,"NetIncomeLoss_1_Q2_USD":-23111000.0,"LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0_Q2_USD":833000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.0001,"PreferredStockSharesIssued_0_Q2_shares":0.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":36832439.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":36847435.0,"VariableLeaseCost_2_Q2_USD":1491000.0,"VariableLeaseCost_1_Q2_USD":727000.0,"SubleaseIncome_2_Q2_USD":1200000.0,"SubleaseIncome_1_Q2_USD":600000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":111000.0,"StockholdersEquity_0_Q2_USD":104190000.0,"ShortTermLeaseCost_2_Q2_USD":0.0,"ShortTermLeaseCost_1_Q2_USD":0.0,"ShareBasedCompensation_2_Q2_USD":3930000.0,"ShareBasedCompensation_1_Q2_USD":2042000.0,"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2_Q2_USD":0.0,"RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_2_Q2_USD":330000.0,"RevenueRemainingPerformanceObligation_0_Q2_USD":14000000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":565000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":279000.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"PreferredStockValue_0_Q2_USD":0.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":3399000.0,"ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_2_Q2_USD":0.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_2_Q2_USD":119470000.0,"ProceedsFromStockOptionsExercised_2_Q2_USD":173000.0,"PreferredStockSharesAuthorized_0_Q2_shares":25000000.0,"PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_0_Q2_USD":3692000.0,"PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_0_Q2_USD":22694000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":18642000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":37368000.0,"RestrictedCash_0_Q2_USD":1733000.0,"RestrictedCashNoncurrent_0_Q2_USD":1733000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-209033000.0,"PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0_Q2_USD":19002000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":36847435.0,"LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_0_Q2_USD":10000000.0,"LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_0_Q2_USD":0.0,"EarningsPerShareBasic_1_Q2_USD":-0.63,"DepreciationDepletionAndAmortization_2_Q2_USD":1556000.0,"DepreciationDepletionAndAmortization_1_Q2_USD":800000.0,"ContractWithCustomerLiabilityNoncurrent_0_Q2_USD":13095000.0,"ContractWithCustomerLiabilityCurrent_0_Q2_USD":910000.0,"ContractWithCustomerLiability_0_Q2_USD":15000000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-46100000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-23127000.0,"CommonStockValue_0_Q2_USD":4000.0,"CommonStockSharesOutstanding_0_Q2_shares":36861350.0,"CommonStockSharesIssued_0_Q2_shares":36861350.0,"CommonStockSharesAuthorized_0_Q2_shares":175000000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.0001,"CommitmentsAndContingencies_0_Q2_USD":null,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":32371000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":126899000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":125166000.0,"AccretionAmortizationOfDiscountsAndPremiumsInvestments_2_Q2_USD":18000.0,"AccruedLiabilitiesCurrent_0_Q2_USD":5152000.0,"AccruedProfessionalFeesCurrent_0_Q2_USD":693000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":-10000.0,"AdditionalPaidInCapital_0_Q2_USD":313229000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":2042000.0,"EarningsPerShareBasic_2_Q2_USD":-1.25,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":6397159.0,"AssetsCurrent_0_Q2_USD":144672000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q2_USD":0.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q2_USD":10000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q2_USD":16117000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q2_USD":16107000.0,"CapitalExpendituresIncurredButNotYetPaid_2_Q2_USD":75000.0,"Assets_0_Q2_USD":208526000.0,"LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_0_Q2_USD":9167000.0,"EarningsPerShareDiluted_1_Q2_USD":-0.63,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":1974000.0,"LongTermDebt_0_Q2_USD":19826000.0,"LiabilitiesCurrent_0_Q2_USD":16414000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":208526000.0,"Liabilities_0_Q2_USD":104336000.0,"LessorOperatingLeasePaymentsToBeReceived_0_Q2_USD":2900000.0,"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0_Q2_USD":13413000.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q2_USD":4941000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q2_USD":10051000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q2_USD":10375000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0_Q2_USD":10623000.0,"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q2_USD":9967000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q2_USD":76533000.0,"LeaseCost_2_Q2_USD":5264000.0,"LeaseCost_1_Q2_USD":2613000.0,"InterestPaidNet_2_Q2_USD":810000.0,"InterestExpense_2_Q2_USD":981000.0,"InterestExpense_1_Q2_USD":495000.0,"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0_Q2_USD":25200000.0,"FairValueAdjustmentOfWarrants_1_Q2_USD":0.0,"FairValueAdjustmentOfWarrants_2_Q2_USD":0.0,"FinanceLeaseLiability_0_Q2_USD":300000.0,"FinanceLeaseLiabilityCurrent_0_Q2_USD":106000.0,"FinanceLeaseLiabilityNoncurrent_0_Q2_USD":198000.0,"EarningsPerShareDiluted_2_Q2_USD":-1.25,"FinanceLeaseRightOfUseAsset_0_Q2_USD":400000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":4898000.0,"GeneralAndAdministrativeExpense_2_Q2_USD":9588000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":-259000.0,"IncreaseDecreaseInAccruedLiabilities_2_Q2_USD":-1699000.0,"IncreaseDecreaseInContractWithCustomerLiability_2_Q2_USD":-565000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":87000.0,"FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_0_Q2_USD":384000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":36832439.0,"Ticker":"FHTX","CIK":"1822462","name":"FOGHORN THERAPEUTICS INC.","OfficialName":"Foghorn Therapeutics Inc. Common Stock","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"553811659.0","Country":"United States","Sector":"Consumer Durables","Industry":"Specialty Chemicals","Market":"NASDAQ","SP500":"nan","filed":"20210810"}]